Controversy over the European Alliance for Access to Safe Medicines and their activities continues. Jim Thomson just won’t go away – still I suppose he needs to earn a living just like the rest of us… I think the accounts of the EAASM will make interesting reading when they’re filed at Companies House.
Earlier this week, the EAASM Harper report was attacked by Heinz Kobert, secretary-general of the parallel importers’ group, the European Association of Euro-Pharmaceutical Companies (EAEPC), who claimed that it made no contribution to the patient safety debate and was about discrediting the “legitimate and safe practice of EU-internal distribution of medicines which introduces price competition for manufacturers”.
Self-appointed ‘patient guardian’ and head of the EAASM Jim Thomson responds to Dr Kobelt:
“…the parallel trade is certainly legal, but whether it is legitimate is open to question…”
“overwhelmingly, the benefit of PPT is primarily accrued by the trader,”
“… as for safety, Dr Kobelt conveniently neglects to mention the tens of thousands of packs of counterfeit medicines that reached UK patients this summer via PPT…”
“…The EAASM report is undoubtedly the most thorough investigation to date of the patient safety implications of PPT and its recommendations represent a massive contribution to the future safety of European patients…”
Just remember Jim’s own words “…ask yourself one question… What does this person, or this organisation, have to gain from taking this position?”
The EAASM is funded by Bayer, Boehringer Ingelheim, Lilly, Pfizer and Wyeth.
For more about Jim and his previous good works please read on:
Jim used to be Sales and Marketing Director for Innervate. Read more on the links below about this: